Hot Investor Mandate: Strategic Fund of Biopharma Company Invests Up to $10M in Digital Health Technologies Targeting Oncology and Infectious Diseases

17 Nov

The strategic fund of a biopharmaceutical company based in Western Europe is aligned with the parent company’s strategy, focusing on technology investments related to oncology and infectious diseases. The firm has $150M under management and invests in the range of $1M – $10M per company. The Fund typically makes a first investment at Series A and currently aims to make 1-3 new equity investments a year.

The firm is mainly seeking digital health and healthcare IT investment opportunities at the pre-commercial or commercial stage that will either improve drug development or that will impact the patient journey (e.g., patient monitoring, digital therapeutics, clinical decision support systems) relating to oncology and infectious diseases.

The firm is very active and supportive of its portfolio companies. The Fund typically takes a board seat, and at times also an observer seat. The Fund is looking for management teams experienced in the domain of interest and with entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Best Practices for Digital RESI November

10 Nov

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

DF-News-09142022Commonality creates dialogue which determines fit. Finding a partner who is a fit for your stage of development and product has to be paramount. Dialogue based on fit facilitates relationships which, when nurtured and developed, leads to friendships and transactions. Building a successful partner relationship requires enhancing your perspective by trying to stand in the other persons shoes and always checking in with simple yet revealing questions.

  • How do you think we are progressing thus far?
  • What are your thoughts about going forward are we moving in the right direction?
  • We have met a few times can you share with me where you are at presently and what you feel needs to get done?

These “check-in” questions are easy to ask and non-threatening but asked at the right time can put you in context on where your potential partner is at.  Being in context is one of the keys to creating a dynamic partnership.

Register-now-button-new

RESI-Nov-2022-Banner-500H-11032022

Interview with Jim MacKrell, Associate Vice President & Head of East Coast (US) Venture Science – Lilly New Ventures, Eli Lilly and Company

10 Nov

By Caitlin Dolegowski, Marketing Specialist, LSN

Jim MacKrell, Associate Vice President & Head of East Coast (US) Venture Science – Lilly New Ventures, Eli Lilly and Company works to identify innovation in core therapeutic areas: diabetes, neuroscience, pain, oncology, and immunotherapy. Lilly New Ventures is expanding its presence in the Boston area and attended RESI Boston as a title sponsor with a goal of expanding relationships with local startups and investors. The diversity and quality of companies and the representation of the Boston life science ecosystem made RESI the right fit for them to “collide with innovators”. Learn more from Jim on Lilly’s focus on genetic medicine, the significance of a balance of persistence and patience that early-stage companies need to have and the importance of strong science.

RESI San Francisco, January 10, followed by two days of virtual, January 11 & 12 is next! Save $300 when you register by November 25 with early bird rates.

Register-now-button-new

RESI-SF-2023-Banner-1100px-11032022

Showcasing Your Company at RESI San Francisco

10 Nov

By Antoinette Lowre, Manager of Business Development, LSN

At our last RESI conference in Boston this past September, we were excited to see so many different company types showcasing their product and/or services. Exhibitors included service providers, tech hub groups, and even some startup companies who brought their products for live demonstrations to the RESI community.

_DSC0509_DSC1087_DSC1179

Exhibiting at RESI is a great way to promote your company and it provides a lot of additional visibility and opportunities to meet other attendees and network in the early-stage life science industry. Click here to learn more about exhibiting at RESI JPM in San Francisco January 10-12.

Register-now-button-new

RESI-SF-2023-Banner-1100px-11032022

Hot Investor Mandate: VC Invests Up to $15M Exclusively in Life Sciences Companies, Most Interested in Novel Therapeutics With China Market Potential

10 Nov

An investment firm headquartered in China invests in Chinese companies, or companies outside of China looking to enter the Chinese market. The firm invests solely in the life sciences, with most (~70%) of their investments in therapeutics companies, and the rest in medical device companies. For most of their investments, the firm participates in the first institutional round, investing between $7-15M, or the equivalent in RMB. The firm invests early, and in some cases acts as a venture builder as well as an investor.

The firm is primarily interested in therapeutics companies, with over half of their investments in this space. The firm is opportunistic in terms of indication, but is especially interested in new modalities within therapeutics, such as cell and gene therapies, or therapeutics in areas with high barriers to entry. For medical devices, the firm prefers technologies relating to surgical robotics and minimally invasive procedures.

The firm is an active investor, almost always taking a board seat and using their network to help the companies advance. This can come in the form of helping them round out their management team, or, if the company is looking to enter the China market, through joint ventures or help navigating the regulatory requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Fund Focuses on Seed-Stage Investments in the Intersection of Science and Technology, Also Interested in Platform Technologies

10 Nov

A seed-stage venture fund is focusing on the frontiers of the intersection of science and technology. The firm looks for companies that are changing the market standards through innovative approaches. The firm is interested in US-based companies and generally invests in seed-series A rounds, typically when less than $5m is being raised. The firm invests in pre-clinical/in development technologies but prefers there to be proof-of-concept data. For medical devices, the firm will consider devices in the 510k regulatory pathway. For all investments, the firm prefers that there is a deep data science or computational element to the technology being commercialized. The firm will generally invest between $250,000-1M, and will often connect companies to larger funds for later capital raises.

The firm is agnostic to sector and indication, and will also consider platform technologies. However, the firm is looking for companies that use DNA and cellular engineering technologies for diagnostics and therapeutics. Ideally, these technologies are also leveraging computation to accomplish their ends. The firm is not interested in standard therapeutics approaches such as small molecules. For medical devices, the firm is looking for devices that change the paradigms of care, solving an unmet need with a unique approach.

The firm does not require a board seat when investing. Rather, the firm will be as involved as necessary to help the company succeed, whether through personal intervention or through a connection to an external expert.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Backed By Investment Ecosystem of Accredited Investors Seeks Early-Stage Investments in Digital Health & Healthtech, Most Interested in USA-Based Companies

10 Nov

An investing ecosystem that includes Accredited Angel Investors, Healthcare Systems, and Corporate Venture Investors focuses on healthcare IT, services and digital health from providers to consumers that changes the landscape of healthcare delivery. The firm prides itself in having built an ecosystem of qualified venture investors, corporate leaders and healthcare providers that open doors to strategic expertise and collaboration in the healthcare IT space. As an Angel-stage investor, the firm’s typical investment size can range, and can go from $100,000 to several million dollars. The firm also co-invests, and has made 24 series A/B investments so far, and is expecting 4-5 new investments and 4-5 repeat investments within the next year. The firm is open to companies throughout the USA, and has historically reviewed companies in Canada, though based on experience, prefer those that can manage the logistics of geographical distance.

The firm focuses on healthcare IT, service, and digital health from providers to consumers that have a working prototype with an early pilot traction. The firm seeks products that serve hospitals at all parts of the continuum care spectrum, reaching to chronic care services that are past discharge and into long-term outpatient care. The firm also invests in devices that go to the consumer, as well as software-enabled technologies, such as connection technologies (i.e. Bluetooth, cell phone, etc.). The firm prefers no FDA regulated devices, and looks at pre-revenue technology with a foreseen horizon in terms of potential. The firm is also open to biotools and lab equipment, as they have historically invested in software and service models in the genomics area and technologies that organize clinical trials.

While a management team must be in place, the firm has an experienced team of members with the ability to mentor and fill management teams with expertise. The firm typically takes a board seat after leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: